MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$130,964K
(-36.80%↓ Y/Y)
Interest income
$12,664K
(-14.63%↓ Y/Y)
Net loss
-$127,845K
(-32.11%↓ Y/Y)
Total other
comprehensive income (gain)
-$3,119K
(-400.19%↓ Y/Y)
Total other income,
net
$12,533K
(-14.34%↓ Y/Y)
Unrealized gain on foreign
currency
$28K
(366.67%↑ Y/Y)
Product
$10,306K
License And Service
$428K
Other expense, net
-$131K
(35.47%↑ Y/Y)
Loss from operations
-$140,378K
(-26.01%↓ Y/Y)
Unrealized loss (gain) on
investment securities
-$3,147K
(-404.65%↓ Y/Y)
Total revenue
$10,734K
(2873.41%↑ Y/Y)
Total operating
expenses
$151,112K
(35.20%↑ Y/Y)
Research and development
$100,081K
(31.27%↑ Y/Y)
Selling, general and
administrative
$50,831K
Cost of product
revenue
$200K
Back
Back
Income Statement
source: myfinsight.com
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)